Hc want let me post external blogs link so here it is pasted...
He said the group's PeriCoach device for female incontinence/libido may be sold in four instalments of $90.
He acknowledged the advisory role Patersons Securities, part-underwriter to the group's recent $3.7m capital raising.
In a formal address lasting one hour - and at informal briefings lasting another 1.5 hours - Daly flagged:
Cash burn in July and August to be higher than normal;
Break-even results in H2/15;
Another capital raising in about 12 months;
Appointment to the board of a director expert in dealing with international regulators;
Eventual female representation on the board and/or in senior management;
Addition of at least three more Australian clinical trial sites;
A major media event featuring a local blogger and a new video produced with top US talent;
A possible change in name from Analytica to PeriCoach;
A PeriCoach data subscription fee, possibly $50;
PeriCoach manufacturing capacity of 2400 units a week could be doubled at a cost of $30k.
Daly, an engineer, indicated the group would not be advertising on TV because of the cost - at least $1m for an ad.
Nor would it be listing on NASDAQ, again because of the cost - at least $2m.
Daly scotched suggestions that the group might collaborate with Philippa Lewis'$SVA/Simavita, the other main Australian player in the female incontinence space.
Would Analytica accept an offer of $50m e.g. from leading US incontinence pads maker Kimberly-Clark? "Yes".
ALT Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
